Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
This work represents one of the first demonstrations of FOXO4-DRI activity in primary human cells, supporting translational relevance beyond the initial mouse model findings
Mild burning, redness, or a small bump can happen and typically resolves quickly
Thinning or fragile skin
saline, TAT-DAT NT or TAT) intracranially
Results continue building with additional cycles
Key takeaways Animal studies show BPC-157 improves gastric motility and protects against gastric damage in rats No human clinical trial has tested BPC-157 for gastroparesis specifically BPC-157 modulates the nitric oxide system and may interact with vagal nerve function, both relevant to gastroparesis Oral administration (250-500 mcg daily) is preferred over injection for GI-targeted effects BPC-157 is unusually stable in stomach acid, making oral delivery viable Patients should work with their gastroenterologist before adding BPC-157 to their gastroparesis management What is gastroparesis and why is it hard to treat
US$ 23.88
US$ 22.76
US$ 27.15
US$ 21.61
US$ 26.75
US$ 28.67
US$ 26.17
US$ 26.56
US$ 24.87
US$ 21.20
US$ 27.14
